Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, FVT

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference


SAN DIEGO, Sept. 16, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that its virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference will take place from 1:20 p.m. to 1:50 p.m. ET on Thursday, September 17, 2020. This is an adjustment from the previously announced date and time.

To access the live and archived webcast of this fireside chat, visit the Investors section of the Evofem Biosciences website at www.evofem.com, and select the Events and Presentations tab. 

Evofem_Logo

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxitm (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into a Phase 3 clinical trial for the prevention of urogenital transmission of both Chlamydia trachomatis and Neisseria gonorrhoeae in women. For more information, please visit www.evofem.com.

Phexxitm is a trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
[email protected]
Office: (858) 550-1900 x167
Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.


These press releases may also interest you

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...

at 02:45
Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024....

at 02:25
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies...

at 02:20
BioInvent International (STO:BINV)"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking...



News published on and distributed by: